{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.46","upperLimit":"0.782","value":"0.632"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"}],"units":"Participants"}],"description":"Major erythroid response is defined as transfusion-independence for ≥ 8 consecutive weeks for patients who were red blood cell transfusion-dependent at baseline AND a ≥ 1 g/dL hemoglobin rise compared to mean pre-transfusion baseline value; or a \\> 2 g/dL rise in hemoglobin without transfusion for non-transfusion dependent patients.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive lenalidomide PO QD on days 1-21.","id":"OG000","title":"Arm A (Lenalidomide; Chromosome 5q31.1 Deletion)"}],"paramType":"NUMBER","populationDescription":"All patients with chromosome 5q31.1 deletion in arm A","reportingStatus":"POSTED","timeFrame":"Assessed after completion of 16 weeks of treatment","title":"Proportion of Patients With Major Erythroid Response (MER) Among Those With Chromosome 5q31.1 Deletion","type":"SECONDARY","unitOfMeasure":"proportion of participants"}